ϟ
DOI: 10.1126/scitranslmed.aax7392
¤ OpenAccess: Green
This work has “Green” OA status. This means it may cost money to access on the publisher landing page, but there is a free copy in an OA repository.
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
Bradon R. McDonald,Tania Contente-Cuomo,Stephen‐John Sammut,Ahuva Odenheimer-Bergman,Brenda Ernst,Nieves Perdigones,Suet-Feung Chin,Maria Farooq,Rosa Mejia,Patricia A. Cronin,Karen S. Anderson,Heidi E. Kosiorek,Donald W. Northfelt,Ann E. McCullough,Bhavika Patel,Jeffrey N. Weitzel,Thomas P. Slavin,Carlos Caldas,Barbara A. Pockaj,Muhammed Murtaza
Neoadjuvant therapy
Breast cancer
Circulating tumor DNA
2019
A robust personalized ctDNA test, TARDIS, achieves high accuracy for residual disease after completion of neoadjuvant therapy.
Loading...
- MLA
- APA
- Chicago
- IEEE
- Harvard
- BibTeX
Cite this:
Generate Citation
“Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer” is a paper by Bradon R. McDonald Tania Contente-Cuomo Stephen‐John Sammut Ahuva Odenheimer-Bergman Brenda Ernst Nieves Perdigones Suet-Feung Chin Maria Farooq Rosa Mejia Patricia A. Cronin Karen S. Anderson Heidi E. Kosiorek Donald W. Northfelt Ann E. McCullough Bhavika Patel Jeffrey N. Weitzel Thomas P. Slavin Carlos Caldas Barbara A. Pockaj Muhammed Murtaza published in 2019. It has an Open Access status of “green”. You can read and download a PDF Full Text of this paper here.